WALTHAM, Mass. / Aug 23, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the 2023 Wells Fargo Healthcare Conference, the Baird 2023 Global Healthcare Conference and the Bank of America European Healthcare Conference.
2023 Wells Fargo Healthcare Conference – Boston, MA
Wednesday, September 6, 2023
8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
Baird 2023 Global Healthcare Conference – New York City, NY
Tuesday, September 12, 2023
9:40 a.m. ET - Prahlad Singh, president and chief executive officer
Bank of America European Healthcare Conference – London, UK
Thursday, September 14, 2023
1:20 p.m. BST - Max Krakowiak, senior vice president and chief financial officer
Attendees will receive an update on the Company and its strategic priorities.
Details on viewing the live audio webcasts will be available on the Investor Relations Events section of the Company’s website. Replays of the presentations will be posted on the Revvity IR website after the events and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Last Trade: | US$110.52 |
Daily Change: | -1.00 -0.90 |
Daily Volume: | 1,092,630 |
Market Cap: | US$13.450B |
February 20, 2025 January 13, 2025 January 12, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load